Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company (Nasdaq: EIKN) founded in 2019 and headquartered in Millbrae, California, with additional offices in New York and Jersey City. Eikon built a proprietary drug-discovery platform around single-molecule live-cell imaging, applying super-resolution fluorescence microscopy and high-throughput single-molecule tracking to observe how proteins and drug targets move and interact inside living cells in real time. The technology descends from co-founder Eric Betzig's Nobel Prize-winning work in super-resolution microscopy, and the company is led by former Merck R&D chief Roger Perlmutter. Eikon uses these measurements to discover and develop novel therapeutics across oncology and other disease areas. This profile was surfaced as a portfolio company of Lux Capital and enriched by the API Evangelist pipeline; Eikon publishes a corporate and investor web presence but no public developer API, SDK, or machine-readable API surface at this time.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Eikon Therapeutics the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Eikon Therapeutics scores 10.8/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Eikon Therapeutics
Each block below is one kind of artifact we hold for Eikon Therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Eikon Therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/eikon-therapeutics · machine-readable index on apis.io